Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Chris Linthwaite, President and CEO, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 9:20 am ET in Boston, Massachusetts. The live audio webcast of the company’s presentation and subsequent replay may be accessed at http://wsw.com/webcast/cowen38/fldm. The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are registered trademarks of Fluidigm Corporation.
Contact: Fluidigm Corporation Ana Petrovic Director, Corporate Development and Investor Relations 650 243 6628 (office) [email protected]
